IPO Allocation Cases Hit Bump In The Road

Will the IPO allocation cases be granted class certification? It seems likely, but the S.D.N.Y. has asked the plaintiffs to provide the court with more information before it will let them proceed against the 55 investment banks named in the suits.

According to a Reuters report, Judge Scheindlin issued an order on Monday giving the plaintiffs two weeks to “redefine the class and convince the court that the definition is adequate.” Moreover, one of the plaintiffs’ primary claims is that the investment banks engaged in “laddering,” a practice in which the banks allegedly handed out IPO shares to buyers who promised to buy more shares at higher prices once the stocks began trading publicly. The alleged goal was to put additional upward pressure on the stock prices. As to these claims, the court stated that the plaintiffs “should report within three weeks on how an expert would measure what effect, if any, was exerted on stock prices” by the alleged laddering.

Quote of note: “In her order, Judge Scheindlin said the court record on whether to grant class status is insufficient in two ways and set tight deadlines for plaintiffs to fill in the gaps. ‘Plaintiffs’ failure to adequately respond to either aspect of this order may result in denial of the pending motions’ seeking class certification, the order said.”

Leave a comment

Filed under IPO Allocation Cases

Fogarazzo Revisited

The decision in the Fogarazzo research analyst case in the S.D.N.Y. (previously posted about in The 10b-5 Daily) is controversial on a number of pleading issues. Not only does the court apply a loss causation standard that, in contravention of the Second Circuit, appears to remove the need to draw any actual connection between the misrepresentations and the loss, it also runs roughshod over other S.D.N.Y. decisions on how to analyze the falsity and scienter (i.e., fraudulent intent) requirements for securities fraud claims based on statements of opinion.

In the research analyst cases, the issue is whether the defendants deliberately misrepresented their truly held opinion that the stock was not a good investment. Judges in the S.D.N.Y. (e.g., Judge Lynch in the Podany decision) have found that under these circumstances the falsity and scienter requirements are essentially identical. Since the statement (unlike a statement of fact) cannot be false at all unless the speaker is knowingly misstating his truly held opinion, the plaintiffs must allege inconsistent statements or actions by the defendants from which a factfinder could infer that a knowing misstatement was made. For example, the plaintiffs might allege that the defendants’ made statements to others that the stock was overvalued or engaged in personal sales of the stock.

In Forgarazzo, Judge Scheindlin rejected this approach. After finding that falsity must be examined separately from scienter, the court held that the falsity of the analysts’ buy recommendations was adequately plead based on allegations that the defendants: (1) wanted to obtain investment banking business from the underlying company; (2) had analysts that were subject to financial conflicts of interest; and (3) failed to maintain adequate controls to protect the objectivity of their public research. None of these allegations, however, suggests that the analyst reports were false (i.e., that the defendants actually regarded the underlying stock as a poor investment). In essence, the court found that the existence of a motive to commit fraud is enough to demonstrate that the opinions were false.

Holding: Motion to dismiss denied.

Leave a comment

Filed under Motion To Dismiss Monitor

Tyson Foods Wins Summary Judgment

The 10b-5 Daily has posted previously about the interesting securities class action brought against Tyson Foods, Inc. in connection with the company’s 2001 acquisition of IBP Inc.

The plaintiffs in the case are a group of hedge funds who were seeking to arbitrage the merger. They allege that on March 29, 2001, Tyson falsely stated that it was backing out of the merger with IBP due to a government investigation into accounting discrepancies at one of IBP’s units. As a result, Tyson artificially deflated the price of IBP’s stock. Tyson eventually completed the acquisition in September 2001, after being ordered to perform on the merger contract by a Delaware state court. The plaintiffs represent all IBP shareholders who bought on or before March 29, 2001, and then sold their shares following Tyson’s announcement.

The Associated Press reports that the D. of Del. has granted summary judgment in favor of Tyson in the case. According to the article, the court found that the father-son team that ran Tyson at the time was “under no duty to tell shareholders the business reasons for their decision not to go forward with the deal.”

Leave a comment

Filed under Summary Judgment

Alpharma Dismissal Affirmed

On Tuesday, the U.S. Court of Appeals for the Third Circuit affirmed the dismissal, with prejudice, of the Alpharma securities class action. See In re Alpharma, Inc. Sec. Litig., 2004 WL 1326013 (3rd Cir. June 15, 2004). A few highlights from the opinion:

(1) Collective scienter – The court appeared to reject the idea that a corporate defendant’s scienter (i.e., fraudulent intent) can be properly alleged on the basis of the collective knowledge of all of the corporation’s officers and employees. The plaintiffs alleged that a sales manager in one of Alpharma’s divisions notified employees in the main office of accounting irregularities. The court held that “the mere fact that the information was sent to Alpharma’s headquarters and therefore was available for review by the individual defendants is insufficient to ‘giv[e] rise to a strong inference that [defendants] acted with the required state of mind.'”

(2) Insider stock sales – The court held that the insider stock sales were not unusual in their scope or timing and, therefore, could not support a strong inference of scienter. The allegation that the defendants had not sold any stock during the preceding fifteen months was deemed insufficient. The defendants asserted they were precluded from selling any stock by a blackout period. Although the court could not technically consider this assertion, it found that the “plaintiffs failed to allege the absence of a blackout period or other facts which would demonstrate that the fifteen month period of inactivity was in any way unusual.”

(3) Leave to amend – The court upheld the district court’s denial of leave to amend where the plaintiffs had failed to proffer any proposed amendment. The denial was “further supported by the fact that plaintiffs (1) had already filed previous complaints and (2) were given an extension of time to assemble the amended consolidated complaint currently at issue.”
Holding: Affirm grant of motion to dismiss with prejudice.

Leave a comment

Filed under Appellate Monitor

Go After The Gatekeepers

For every commentator who believes that Congress has gone too far in passing corporate reforms, there is another who believes that Congress needs to take immediate additional action. In this column from CBS MarketWatch, the author argues that the PSLRA should be overhauled to make it easier for investors to bring suit and new reforms should be passed to address the failings of lawyers, accountants, and Wall Street firms to prevent fraud.

Quote of note: “The real problem is the lack of ‘vicarious liability,’ whereby institutional gatekeepers are held accountable for misdeeds as much as the organizations from which they supposedly protect the public.”

Leave a comment

Filed under All The News That's Fit To Blog

Running Loss Causation Out of Town

The argument that loss causation must be plead by showing a stock price decline related to the alleged fraud, articulated in the Second Circuit by the Emergent Capital decision, is meeting with increased resistance by the S.D.N.Y. judges handling the research analyst cases. Judges have argued that the stock market crash that occured between the issuance of the allegedly biased research and the revelation of the analysts’ conflicts of interest (and, therefore, arguably caused any loss) was irrelevant, either because of allegations that the research analyst directly participated in a fraudulent scheme perpetrated by the issuer of the underlying stock or because the revelation of the analysts’ conduct caused a subsequent stock price drop. (See these posts on the WorldCom and Robertson Stephens cases).

In Fogarazzo v. Lehman Brothers, Inc., 2004 WL 1151542 (S.D.N.Y. May 21, 2004), however, the entire concept of the price decline approach to pleading loss causation comes under attack. The complaint, brought by shareholders of RSL Communications, Inc. (“RSL”), alleged that analysts at three firms had falsified their opinions of RSL. Specifically, while RSL issued a series of negative announcements in 1999 and 2000 – and its stock price dropped – the analysts continued to provide RSL with positive ratings. Ultimately, RSL’s stock declined to the point that it was delisted, and each of the three firms then dropped analyst coverage. The court was careful to note that there were no allegations that the defendants concealed any facts concerning RSL. Instead, the plaintiffs merely alleged that despite publicly available negative information, the analysts expressed falsely positive opinions.

Although the facts are similar to those in the Merrill Lynch cases, Judge Scheindlin appears to create a new loss causation standard and concludes that loss causation was adequately plead. The court explained that loss causation is shown when “(1) the misrepresentation artificially inflated the value of the security, or otherwise misrepresented its investment quality, and (2) the subject of the misrepresentation causedthe decline in the value of the security.” Here, the subject of the misrepresentations was “the financial health and future prospects of RSL,” and though no facts were concealed, that subject still caused plaintiffs’ losses. “[E]ven though the true facts were available to the world to see, by affirmatively opining on the meaning of those facts, the Banks obscured the logical conclusion that RSL was failing.” This standard would appear to remove the need to draw any actual connection between the misrepresentations and the loss; the mere fact that the company’s stock price declined creates liability for anyone who issued false statements about the company into the market.

Moreover, although Judge Scheindlin expressed uncertainty as to whether the Second Circuit’s price decline approach requires a corrective disclosure, the court concluded that dropping analyst coverage of RSL was a corrective disclosure. “[W]hen the Banks dropped coverage, they essentially conceded (in the eyes of the investing public) that their previous recommendations were mistaken.” Even accepting this characterization of the banks’ actions (and it is hard to see how dropping coverage can be equated with a disclosure about the previous recommendations), the court did not find that there was a price decline after coverage was dropped.

As noted previously, clarification of these issues may come in the near future. The Second Circuit is scheduled to hear the appeal of the first few Merrill Lynch decisions on August 12, 2004.

Holding: Motion to dismiss denied. (The 10b-5 Daily may do an additional post about the other holdings in the opinion.)

Leave a comment

Filed under Motion To Dismiss Monitor

Round And Round It Goes

The shakeup in the plaintiffs’ securities bar continues with today’s announcement that Lerach Coughlin Stoia & Robbins will combine with Geller Rudman. The merger will expand Lerach Coughlin’s presence on the east coast, adding offices in New York and Florida.

As of August 1, 2004, the combined firm will be known as Lerach Coughlin Stoia Geller Rudman & Robbins LLP and will have approximately 140 lawyers. Both firms are the products of recent splits.

Leave a comment

Filed under All The News That's Fit To Blog

Using Stock As Currency

As noted in The 10b-5 Daily’s discussions of the Intergroup and NUI decisions, the idea that corporate acquisitions for stock are a sufficient motive for securities fraud is controversial. A contrary view can be found in the recent decision in In re Corning Sec. Litig., 2004 WL 1056063 (W.D.N.Y. April 9, 2004).

In the Corning case, the plaintiffs alleged that the defendants were motivated to artificially inflate the company’s stock price so that they could use it as currency for the acquisition of Tropel Corporation. The court found that “[p]aying a smaller price for the acquisition of Tropel [by using inflated stock] benefited Corning’s common shareholders.” Moreover, the desire to have a high stock price to be used in the purchase of Tropel “is a motive that could be attributed to virtually every company seeking to acquire another through the use of its own stock as part of the purchase.” As a result, the court held that the acquisition failed to create a strong inference of scienter.

Holding: Motion to dismiss granted.

Leave a comment

Filed under Motion To Dismiss Monitor

Providian Settles

Providian Financial Corp. (NYSE: PVN), a San Francisco-based provider of consumer credit cards, has announced the preliminary settlement of the securities class action pending against the company in the N.D. of Cal. The suit, originally filed in 2001 and about to go to trial, alleges that the company made misrepresentations concerning its operations and prospects. The settlement is for $65 million, to be paid by Providian’s insurance carriers.

Leave a comment

Filed under Settlement

Honeywell and Symbol Technologies Settle

Two large settlements from the end of last week:

Honeywell Int’l, Inc. (NYSE: HON), a New Jersey-based diversified manufacturer, has announced the preliminary settlement of the securities class action pending against the company in the D. of N.J. The suit, originally filed in 2002 and currently in discovery, alleges that Honeywell made false and misleading statements relating to the 1999 AlliedSignal/Honeywell merger and its financial performance. Under the terms of the settlement, Honeywell has agreed to pay $100 million into an escrow fund, with $85 million coming from its insurers.

Symbol Technologies, Inc. (NYSE: SBL), a New York-based manufacturer of bar scanner-integrated mobile and wireless information management systems, has announced the preliminary settlement of the securities class action pending against the company in the E.D.N.Y. (as well as settlements with the DOJ and SEC). The suit, originally filed in 2002, alleges that the company made false and misleading statements relating to accounting issues. The settlement is valued at $139 million, including $96.25 million in common stock, $5.75 million in cash (from the company and its ex-CEO), and $37 million in cash from the company as part of a joint compensation fund created in the DOJ settlement. Lead counsel for the class has also issued a press release.

Leave a comment

Filed under Settlement